BPRO yields 9.01% · JNJ yields 2.14%● Live data
📍 BPRO pulled ahead of the other in Year 1
Combined, BPRO + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BPRO + JNJ for your $10,000?
BPRO seeks capital appreciation by investing in assets resilient to currency debasement, or the decline in major currencies value or purchasing power. Debasement-resistant assets (considered difficult to inflate or manipulate) include gold and other precious metals, as well as digital assets such as Bitcoin. The Fund invests in ETPs holding these assets and in ETFs with exposure to precious metal miners. Investments may include equity or debt securities issued by relevant companies, as well as sovereign debt, global currencies, and structured products or geared ETPs linked to these asset classes. Investments are not fixed, and selection utilizes macroeconomic views and proprietary modeling, which is reviewed at least weekly. The actively managed fund is expected to have significant gold exposure and does not invest directly in cryptocurrency. BPRO may use options contracts, taking different positions based on expected price movements of the underlying assets.
Full BPRO Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.